Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis

被引:0
|
作者
A P Costa-Pereira
T G Cotter
机构
[1] Tumour Biology Laboratory,Department of Biochemistry
[2] University College,undefined
来源
British Journal of Cancer | 1999年 / 80卷
关键词
apoptosis; prostate cancer; Fas; caspases; reactive oxygen intermediates;
D O I
暂无
中图分类号
学科分类号
摘要
Despite expressing both Fas and Fas ligand, DU145 and LNCaP prostate cancer cells were resistant to anti-Fas-induced cell death. Resistance to Fas-mediated cytotoxicity could be overcome in DU145, but not in LNCaP, cells by pretreating cells with sublethal doses of cytotoxic drugs, such as camptothecin. Activated caspases were shown to be required for this cytotoxicity. Indeed, poly(ADP-Ribose) polymerase was shown to be proteolytically cleaved in cells treated with camptothecin plus anti-Fas, but not in cells treated with anti-Fas only. Moreover, pretreatment of cells with ZVAD completely blocked camptothecin-mediated Fas-induced apoptosis. Sensitization of cells to Fas-induced cell death did not involve up-regulation of Fas or FasL, and it was independent of alterations in the cell cycle. Reactive oxygen intermediates (ROI) have been shown to be important mediators of drug-induced apoptosis. Here, we demonstrate that treatment of DU145 cells with camptothecin, anti-Fas, or both, did not alter the intracellular levels of peroxide or superoxide anion.
引用
收藏
页码:371 / 378
页数:7
相关论文
共 50 条
  • [41] Therapeutic potential of curcumin in human prostate cancer - I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells
    Dorai, T
    Gehani, N
    Katz, A
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (02) : 84 - 93
  • [42] Inhibition of Fas Receptor Endocytosis Sensitizes Cancer Cells to Fas-induced Apoptosis
    Kural, C.
    Kural, M.
    Niklason, L.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S50 - S51
  • [43] Stem cell genes in androgen-independent prostate cancer
    Bui, M
    Reiter, RE
    CANCER AND METASTASIS REVIEWS, 1998, 17 (04) : 391 - 399
  • [44] New features in the treatment of androgen-independent prostate cancer
    Closset, J
    Ammar, H
    Nguyen, VH
    Cornet, A
    Reiter, E
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (05) : 513 - 522
  • [45] Stem Cell Genes in Androgen-independent Prostate Cancer
    Matthew Bui
    Robert E. Reiter
    Cancer and Metastasis Reviews, 1998, 17 : 391 - 399
  • [46] Low PSA metastatic androgen-independent prostate cancer
    Sella, A
    Konichezky, M
    Flex, D
    Sulkes, A
    Baniel, J
    EUROPEAN UROLOGY, 2000, 38 (03) : 250 - 254
  • [47] Development of the VCaP androgen-independent model of prostate cancer
    Loberg, RD
    St John, LN
    Day, LL
    Neeley, CK
    Pienta, KJ
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (02) : 161 - 168
  • [48] Future directions in the treatment of androgen-independent prostate cancer
    Petrylak, DP
    UROLOGY, 2005, 65 (6A) : 8 - 12
  • [49] Proteomic Signatures of Angiogenesis in Androgen-Independent Prostate Cancer
    Karagiannis, George S.
    Saraon, Punit
    Jarvi, Keith A.
    Diamandis, Eleftherios P.
    PROSTATE, 2014, 74 (03): : 260 - 272
  • [50] Sorafenib Sensitizes (-)-Gossypol-Induced Growth Suppression in Androgen-Independent Prostate Cancer Cells via Mcl-1 Inhibition and Bak Activation
    Lian, Jiqin
    Ni, Zhenhong
    Dai, Xufang
    Su, Chang
    Smith, Amber Rae
    Xu, Liang
    He, Fengtian
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 416 - 426